SARS-CoV-2 Inhibitors Identified by Phenotypic Analysis of a Collection of Viral RNA-Binding Molecules

dc.contributor.authorSimba Lahuasi, Alvaro
dc.contributor.authorCantero Camacho, Ángel
dc.contributor.authorRosales, Romel
dc.contributor.authorMcGovern, Briana Lynn
dc.contributor.authorRodríguez, M. Luis
dc.contributor.authorMarchán Sancho, Vicente
dc.contributor.authorWhite, Kris M.
dc.contributor.authorGarcía Sastre, Adolfo
dc.contributor.authorGallego, José
dc.date.accessioned2023-02-16T11:46:04Z
dc.date.available2023-02-16T11:46:04Z
dc.date.issued2022-11-22
dc.date.updated2023-02-16T11:46:04Z
dc.description.abstractAntiviral agents are needed for the treatment of SARS-CoV-2 infections and to control other coronavirus outbreaks that may occur in the future. Here we report the identification and characterization of RNA-binding compounds that inhibit SARS-CoV-2 replication. The compounds were detected by screening a small library of antiviral compounds previously shown to bind HIV-1 or HCV RNA elements with a live-virus cellular assay detecting inhibition of SARSCoV-2 replication. These experiments allowed detection of eight compounds with promising antiSARS-CoV-2 activity in the sub-micromolar to micromolar range and wide selectivity indexes. Examination of the mechanism of action of three selected hit compounds excluded action on the entry or egress stages of the virus replication cycle and confirmed recognition by two of the molecules of conserved RNA elements of the SARS-CoV-2 genome, including the highly conserved S2m hairpin located in the 3'-untranslated region of the virus. While further studies are needed to clarify the mechanism of action responsible for antiviral activity, these results facilitate the discovery of RNA-targeted antivirals and provide new chemical scaffolds for developing therapeutic agents against coronaviruses.
dc.format.extent17 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec729642
dc.identifier.issn1424-8247
dc.identifier.urihttps://hdl.handle.net/2445/193697
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ph15121448
dc.relation.ispartofPharmaceuticals, 2022, vol. 15, p. 1448
dc.relation.urihttps://doi.org/10.3390/ph15121448
dc.rightscc-by (c) Simba Lahuasi, Alvaro et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Química Inorgànica i Orgànica)
dc.subject.classificationCOVID-19
dc.subject.classificationRNA
dc.subject.otherCOVID-19
dc.subject.otherRNA
dc.titleSARS-CoV-2 Inhibitors Identified by Phenotypic Analysis of a Collection of Viral RNA-Binding Molecules
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
729642.pdf
Mida:
740.26 KB
Format:
Adobe Portable Document Format